Advanced Biomedical Company Insiders
| ABMT Stock | USD 0.0001 0.00 0.00% |
Advanced Biomedical employs about 17 people. The company is managed by 5 executives with a total tenure of roughly 33 years, averaging almost 6.0 years of service per executive, having 3.4 employees per reported executive. Breaking down Advanced Biomedical's management performance can provide insight into the firm performance.
| Hui Wang CEO CEO, Controller, Director and Member of Disclosure Committee |
| Pr MD Chairman Chairman China |
Advanced |
Advanced Biomedical Management Team Effectiveness
The company has return on total asset (ROA) of (0.7811) % which means that it has lost $0.7811 on every $100 spent on assets. This is way below average. Advanced Biomedical's management efficiency ratios could be used to measure how well Advanced Biomedical manages its routine affairs as well as how well it operates its assets and liabilities.Advanced Biomedical Workforce Comparison
Advanced Biomedical Technologies is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 294,817. Advanced Biomedical adds roughly 17.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Advanced Biomedical Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Advanced Biomedical Price Series Summation is a cross summation of Advanced Biomedical price series and its benchmark/peer.
Advanced Biomedical Notable Stakeholders
An Advanced Biomedical stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Advanced Biomedical often face trade-offs trying to please all of them. Advanced Biomedical's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Advanced Biomedical's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Hui Wang | CEO, Controller, Director and Member of Disclosure Committee | Profile | |
| Pr MD | Chairman China | Profile | |
| Chi Yu | President, Treasurer, Compliance Officer, Director and Member of Disclosure Committee | Profile | |
| Kai Gui | CFO, Secretary, Director and Member of Disclosure Committee | Profile | |
| John Lynch | Chief Technologies | Profile |
About Advanced Biomedical Management Performance
The success or failure of an entity such as Advanced Biomedical often depends on how effective the management is. Advanced Biomedical management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Advanced management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Advanced management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Advanced Biomedical Technologies, Inc., a development stage company, designs, develops, manufactures, and markets biomaterial internal fixation devices. Advanced Biomedical Technologies, Inc. was founded in 2002 and is based in New York, New York. Advanced Biomedical operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 17 people.
Please note, the imprecision that can be found in Advanced Biomedical's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Advanced Biomedical Technologies. Check Advanced Biomedical's Beneish M Score to see the likelihood of Advanced Biomedical's management manipulating its earnings.
Advanced Biomedical Workforce Analysis
Traditionally, organizations such as Advanced Biomedical use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Advanced Biomedical within its industry.Advanced Biomedical Manpower Efficiency
Return on Advanced Biomedical Manpower
| Revenue Per Employee | 7.3K | |
| Revenue Per Executive | 24.7K | |
| Net Loss Per Employee | 39.5K | |
| Net Loss Per Executive | 134.4K |
Additional Tools for Advanced Pink Sheet Analysis
When running Advanced Biomedical's price analysis, check to measure Advanced Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Advanced Biomedical is operating at the current time. Most of Advanced Biomedical's value examination focuses on studying past and present price action to predict the probability of Advanced Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Advanced Biomedical's price. Additionally, you may evaluate how the addition of Advanced Biomedical to your portfolios can decrease your overall portfolio volatility.